

AD _____

Award Number: DÁMD17-02-1-0118

TITLE: Genetic Alterations in Epithelial and Stromal
Compartments of Prostate Adenocarcinomas

PRINCIPAL INVESTIGATOR: Charis Eng, M.D., Ph.D.

CONTRACTING ORGANIZATION: The Ohio State University
Columbus, OH 43210-1063

REPORT DATE: January 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040524 145

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE January 2004	3. REPORT TYPE AND DATES COVERED Annual (15 Dec 2002 - 14 Dec 2003)	
4. TITLE AND SUBTITLE Genetic Alterations in Epithelial and Stromal Compartments of Prostate Adenocarcinomas		5. FUNDING NUMBERS DAMD17-02-1-0118	
6. AUTHOR(S) Charis Eng, M.D., Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Ohio State University Columbus, OH 43210-1063 E-Mail: eng-1@medctr.osu.edu		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Genetic analyses on prostate cancer has been occurring for over a decade. However, such studies were uniformly performed on the entire tumor without regard to its components despite the fact that a few groups were quite aware of both epithelial and stromal components of tumors, and the cell biology of the tumor "microenvironment" has been described for the last 20 years. Thus, until now, when a genetic alteration, be it intragenic mutation, regional amplification, or deletion manifested by loss of heterozygosity of markers (LOH) is attributed to a prostate cancer, it is unclear if the alteration is actually occurring in the epithelial compartment, the surrounding stromal compartment or both. Our own preliminary data on breast carcinomas demonstrate that LOH and even somatic mutations can occur in surrounding stromal fibroblasts. Therefore, this proposal proposes to search for genetic alterations in the stroma of prostate cancers and to determine if such alterations can influence clinical outcome. In the second year,			
14. SUBJECT TERMS Human cancer genetics, prostate cancer stroma			15. NUMBER OF PAGES 11
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

Cover.....	
SF 298.....	1
Table of Contents.....	2
Introduction.....	3
Body.....	3
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusions.....	5
References.....	5
Appendices.....	6

Year 2 Annual Report

Proposal Title: Genetic alterations in epithelial and stromal compartments of prostate adenocarcinomas

PI: Charis Eng, MD, PhD

INTRODUCTION

Prostate cancer is common in the West and is uniformly lethal once metastasized. Thus, there is growing interest in examining the genetic alterations in prostate cancer. Until recently, however, solid tumors such as prostate carcinoma was treated as a single amorphous entity. Genetic studies were uniformly performed on the entire tumor without regard to its components despite the fact that a few groups were quite aware of both epithelial and stromal components of tumors, and the cell biology of the tumor "microenvironment" has been described for the last 20 years. Thus, until now, when a genetic alteration, be it intragenic mutation, regional amplification, or deletion manifested by loss of heterozygosity of markers (LOH) is attributed to a prostate cancer, it is unclear if the alteration is actually occurring in the epithelial compartment, the surrounding stromal compartment or both. Recently, Moinfar and colleagues, using a limited subset of samples and markers, demonstrated that LOH of markers representing three chromosomal loci can occur in the stromal compartment of a small pilot series of invasive breast adenocarcinomas (1). Further, the PI has demonstrated LOH of a limited set of markers in the stroma of invasive breast adenocarcinomas (2). More importantly, somatic intragenic mutations of *TP53* and *PTEN* have been found in the stroma, but are mutually exclusive within any single compartment (3). This has never been examined in prostate or other cancers. Nonetheless, the mechanisms, especially the genetic mechanisms, by which the different cells in the micro-environment interact with the epithelial component to initiate and/or promote tumor growth is not well understood. Thus, the overall hypothesis of the submitted proposal was that genetic changes in the stromal and epithelial compartment of prostate adenocarcinomas differentially contribute to tumor growth, such that they affect clinical outcomes differently. The hypothesis is to be addressed by two Objectives:

1. To determine the relative frequency of genetic alterations within the stromal versus epithelial compartment of human prostate adenocarcinomas and to build a genetic model for multistage stepwise carcinogenesis involving the epithelium and stroma in prostate cancer;
2. To determine the clinical consequences of genetic alterations within the stromal versus epithelial compartment of adenocarcinomas of the prostate.

BODY

Objective 1: To determine the relative frequency of genetic alterations within the stromal versus epithelial compartment of human prostate adenocarcinomas, and to build a genetic model for multistage stepwise carcinogenesis involving the epithelium and stroma in prostate cancer

This objective can be viewed as a two-stage task. The first step is the accrual of prostate cancer specimens for the analysis. The second step is laser capture microdissection (LCM) of neoplastic epithelium, surrounding stroma, and corresponding non-neoplastic germline tissue, followed by total genome LOH scanning and final analyses. At the end of Year 1, the PI reported procuring epithelial and stromal cells by LCM from 55 non-M1 prostate adenocarcinomas and that a total genome scan was commencing. Unfortunately, after almost 9 months of attempting a genome scan with the Research Genetics set of 400 markers, the PI and team have ascertained that the DNA from all but 5 samples were so degraded (or the formalin may not have been buffered) that PCR was impossible. This is not a systematic technical issue in the PI's lab because the PI has just successfully completed a 389-microsatellite marker total genome LOH scan of DNA from LCM-procured cells in the epithelial and stromal compartments of 125 sporadic invasive adenocarcinomas of the breast (Eng, unpublished) and completed a 389-marker total genome LOH scan as well as *TP53* mutation analysis of DNA from epithelial and stromal compartments LCM-procured from 12 invasive adenocarcinomas of the breast originating from individuals with germline *BRCA1/2* individuals (funded by DOD BCRP). Thus, in the latter 3 months of Year 2, the PI has changed sources (dates – obtaining newer blocks which is a trade off for longer follow up) for obtaining prostate adenocarcinoma archived blocks. In the last 3 months, the PI has obtained 20 blocks, non-M1 and >90% Gleason's score 2+2 and 2+3 (or 3+2), as a pilot. Genomic DNA from stroma and epithelium from 10 prostate adenocarcinomas with Gleason score 2+2 have been obtained and a 389-marker (Research Genetics) total genome LOH scan successfully completed. Inspection demonstrates LOH of markers in the epithelial and/or stromal compartments. The PI will therefore continue to accrue non-M1 prostate adenocarcinoma samples from similar sources as the initial batch of 20.

Objective 2: To determine the clinical consequences of genetic alterations within the stromal versus epithelial compartment of adenocarcinomas of the prostate

This objective is entirely dependent on completion of the total genome LOH scan and analysis as proposed in Objective 1 (which is envisioned to complete in the final quarter of Year 3). While we are trading off shorter follow-up for technical success, the initial new batch of 20 all have clinico-pathologic information linked to the samples.

KEY RESEARCH ACCOMPLISHMENTS

The first 20 prostate adenocarcinoma samples with full clinical and pathologic information have been accrued, and subjected to LCM and DNA extraction. Total genome scanning has successfully been completed on 10 with differential LOH of markers in epithelial and/or stromal compartments observed.

REPORTABLE OUTCOMES

Elected Fellow, AAAS, Sept., 2003

Chair, Scientific Program Committee, 53rd Annual Meeting of the American Society of Human Genetics, Los Angeles, CA, Nov. 4-8, 2003

CONCLUSIONS

The first nine months of the second year of this project was mainly dedicated to technically achieving a total genome scan on epithelium and stroma LCM-procured from the first 55 samples from Year 1. Unfortunately either because of massive degradation of nucleic acids and/or non-buffered formalin of these samples, PCR was impossible despite massive efforts. This was not due to systematic issues in the PI's lab as the PI has completed total genome LOH scans from LCM-procured epithelium and stroma from >100 breast adenocarcinoma samples. Nonetheless, a separate set of 20 non-M1 prostate adenocarcinomas (more recent samples) were accrued in the latter 3 months, 10 of which have had epithelial and stromal cells procured by LCM, and subjected to a total genome LOH scan. Inspection reveals LOH of certain markers in the epithelium and/or stroma. We are not able to rapidly accrue the remaining samples and subject them to total genome LOH scanning, without further issues.

REFERENCES CITED

1. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. *Cancer Res.* 2000;60:2562-2566.
2. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. *Hum. Mol. Genet.* 2001;10:1907-1913.
3. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in *PTEN* and *TP53* are mutually exclusive in the stroma of breast carcinomas. *Nature Genet.* 2002;32:355-357.

APPENDIX

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Eng, Charis, M.D., Ph.D.		POSITION TITLE Professor of Medicine/Principal Investigator	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Chicago, Chicago, IL	B.A.	1978-82	Biological Sci
University of Chicago, Chicago, IL	Ph.D.	1982-86	Development. Bio
University of Chicago, Chicago, IL	M.D.	1982-88	Medicine
University of Cambridge, Cambridge, UK	(Post-Doc)	1992-95	Cancer Genetics

A. Positions and Honors*Academic Appointments*

- 1988-1991 Residency in Internal Medicine, Beth Israel Hospital, Boston, MA
 1991-1994 Clinical Fellowship, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
 1992-1995 CRC Dana-Farber Fellowship in Human Cancer Genetics, University of Cambridge, UK
 1992-1995 Senior Registrar in Clinical Cancer Genetics, University of Cambridge Addenbrooke's Hospital, Cambridge, UK and Royal Marsden Hospital, London, UK
 1994-1995 Instructor in Medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
 1995-1998 Assistant Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston
 1995-1998 Active Staff Physician, Adult Oncology, Dana-Farber Cancer Institute, Boston, MA
 1995-1998 Associate Physician, Brigham and Women's Hospital, Boston, MA
 1999-2002 Associate Professor (with tenure) of Medicine, The Ohio State University, Columbus, OH
 1999-present Director, Clinical Cancer Genetics Program, James Cancer Hospital and Solove Research Institute, Comprehensive Cancer Center, Ohio State University, Columbus, OH
 2001-present William C. and Joan E. Davis Professor of Cancer Research, The Ohio State University
 2002-present Professor (with Tenure) of Medicine, The Ohio State University, Columbus, OH
 2002-present Dorothy Klotz Chair of Cancer Research, The Ohio State University, Columbus, OH
 2002-present Director, Division of Human Genetics, Department of Internal Medicine, The Ohio State University

Honors and Awards

- 1982 Phi Beta Kappa
 1982 Sigma Xi Associate Membership and Sigma Xi Prize
 1987 Sigma Xi Promotion to Full Membership
 1988 Alpha Omega Alpha
 1995 First Lawrence & Susan Marx Investigator in Human Cancer Genetics, Dana-Farber Cancer Institute
 1999 American College of Physicians, Promotion to Fellowship
 2001 Elected Member, American Society for Clinical Investigation
 2002 Harry de Lozier Memorial Lecturership
 2002 Stephanie Spielman Breast Cancer Research Award, The Ohio State University, Columbus
 2002 Doris Duke Distinguished Clinical Scientist Award (2002-2007)
 2003 Elected Fellow, AAAS

Selected Recent Additional Professional Activities

- 1998-present North American Editor and Cancer Genetics Editor, *Journal of Medical Genetics*
 1998-present NCCN Genetics/High Risk Screening Panel
 2001-2003 American Soc. of Clinical Oncology Subcommittee to Revise Guidelines for Cancer Genetic Testing
 2001-present American Cancer Society Molecular Biology and Oncogenes Study Section

B. Selected Publications (selected from a total of 203 peer reviewed original publications)

Nelen MR, Padberg GW, Peeters EAJ, Ponder BAJ, Ropers HH, Kremer H, Longy M, **Eng C**. Localization of the gene for Cowden disease to 10q22-23. *Nature Genet*, 13:114-116, 1996.

Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ponder BAJ, Mulligan LM. The relationship between specific *RET* proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International *RET* Mutation Consortium analysis. *JAMA*, 276:1575-1579, 1996.

Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, **Eng C***, Parsons R*. Germline mutations of the *PTEN* gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nature Genet*, 16:64-67, 1997. (*Joint Senior Authorship noted on the article)

- Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PLM, Zheng Z, 28 others, Parsons R, Peacocke M, Longy M, **Eng C**. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline *PTEN* mutation. *Hum Mol Genet*, 7:507-515, 1998.
- Eng C**, Peacocke M. *PTEN* mutation analysis as a molecular diagnostic tool in the inherited hamartoma-cancer syndromes. *Nature Genet*, 19:223, 1998.
- Marsh D, Kum J, Lunetta K, 28 others, Weng L, Dahia P, **Eng C**. *PTEN* mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. *Hum Mol Genet*, 8:1461-72, 1999.
- Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Speigelman BM, **Eng C**. Loss of function mutations in *PPARgamma* associated with human colorectal cancer. *Mol Cell*, 3:799-804, 1999.
- Perren A, Weng LP, Boag AH, Ziebold U, Kum JB, Dahia PLM, Komminoth P, Lees JA, Mulligan LM, Mutter GL, **Eng C**. Immunocytochemical evidence of loss of *PTEN* expression in primary ductal adenocarcinomas of the breast. *Am J Pathol*, 155:1253-1260, 1999.
- Weng LP, Smith WM, Dahia PLM, Ziebold U, Gil E, Lees JA, Eng C. *PTEN* suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. *Cancer Res*, 59:5808-5814, 1999.
- Mutter GL, Lin M-C, FitzGerald JT, Kum JB, Baak JPA, Lees JA, Weng LP, **Eng C**. Altered *PTEN* expression as a molecular diagnostic marker for the earliest endometrial precancers. *J Natl Cancer Inst*, 92:924-931, 2000.
- Gimm O, Attié-Bitach T, Lees JA, Vekemans M, **Eng C**. Expression of the *PTEN* tumour suppressor protein in human embryonic development. *Hum Mol Genet*, 9:1633-1639, 2000.
- Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU, **Eng C**. Mutation and expression analyses reveal differential subcellular compartmentalization of *PTEN* in endocrine pancreatic tumors compared to normal islet cells. *Am J Pathol*, 157:1097-1103, 2000.
- Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, **Eng C**. Epigenetic *PTEN* silencing in malignant melanomas without *PTEN* mutation. *Am J Pathol*, 157:1123-1128, 2000.
- Weng LP, Brown JL, **Eng C**. *PTEN* induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways. *Hum Mol Genet*, 10:237-242, 2001.
- Weng L, Gimm O, Kum J, Smith W, Zhou X, Thomas D, Leone G, **Eng C**. Transient ectopic expression of *PTEN* in thyroid cancer cell lines induce cell cycle arrest & cell type-dependent cell death. *Hum Mol Genet*, 10:251-258, 2001.
- Weng L, Brown J, **Eng C**. *PTEN* coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity & up regulating p27 via its lipid phosphatase activity in a breast cancer model. *Hum Mol Genet*, 10:599-604, 2001.
- Weng L, Smith W, Brown J, **Eng C**. *PTEN* inhibits insulin-stimulated MEK/MAPK activation & cell growth by blocking IRS-1 phosphorylation & IRS-1/Grb-2/Sos complex formation in breast cancer model. *Hum Mol Genet*, 10:605-616, 2001.
- Mutter GL, Ince T, Baak JPA, Kurst GA, Zhou XP, **Eng C**. Molecular identification of latent precancers in histologically normal endometrium. *Cancer Res* 2001; 61:4311-4.
- Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RCM, Parisi M, Winter RM, **Eng C**. Association of germline mutation in the *PTEN* tumor suppressor gene and a subset of Proteus and Proteus-like syndromes. *Lancet*, 358:210-211, 2001.
- Kurose K, Woodard S, Adeyinka A, Lemeshow S, Watson P, **Eng C**. Genetic model of multi-step breast carcinogenesis involving epithelium & stroma: clues to tumour-microenvironment interactions. *Hum Mol Genet*, 10(18):1907-13, 2001.
- Zhou XP, Kuismanen S, Nyström-Lahti M, Peltomäki P, **Eng C**. Distinct *PTEN* mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. *Hum Mol Genet*, 11(4):445-450, 2002.
- Neumann HPH, Bausch B, McWhinney S, Bender B, Gimm O, Franke G, Schipper J, Klisch J, Althöfer C, Zerres K, Januszewicz A, **Eng C**. Germ-line mutations in nonsyndromic pheochromocytoma. *N Engl J Med*, 346:1459-66, 2002.
- Weng LP, Brown JL, Baker KM, Ostrowski MC, **Eng C**. *PTEN* blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independent of the phosphoinositide-3-kinase pathway. *Hum Mol Genet*, 11:1687-1696, 2002.
- Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, **Eng C**. Frequent *PTEN* and *TP53* somatic mutations are mutually exclusive in the stroma of breast carcinomas. *Nature Genet*, 32:355-357, 2002.
- Borrego S, Wright F, Fernández R, Williams N, López-Alonso M, Davuluri R, Antiñolo G, Eng C. A founding locus within the *RET* proto-oncogene may account for the majority of apparently sporadic Hirschsprung disease. *Am J Hum Genet*. 72:88-100, 2003.
- Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0G1 in MCF-7 cells. *Cancer Res*. 63:282-286, 2003.
- Waite K, **Eng C**. BMP2 exposure results in decreased *PTEN* protein degradation leading to increased *PTEN* levels. *Hum Mol Genet*, 12:679-84, 2003.
- Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, **Eng C**. *Caveolin-1* and *caveolin-2*, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors downregulated in sporadic follicular thyroid carcinogenesis. *Cancer Res*, 63:2864-71, 2003.
- Zhou XP, Waite KA, 12 others, Nassif NT, **Eng C**. Germline *PTEN* promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant *PTEN* protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. *Am J Hum Genet*, 73:404-11, 2003.

C. Research Support**Ongoing Research Support**

07/01/01-06/30/05

1) NIH/NICHD 1 R01 HD39058-01A1

Title: RET complex polymorphisms in Hirschsprung disease

PI: Charis Eng, M.D., Ph.D.

The goal of this project is to identify and characterize common low penetrance alleles within RET and the genes which encode its ligands and co-ligands in "sporadic" medullary thyroid carcinoma as well as sporadic Hirschsprung disease.

07/01/02-06/30/06

2) American Cancer Society RSG-02-151-01-CCE

Title: Genetics of PTEN in Cowden and Related Syndromes and Familial Cancer

PI: Charis Eng, M.D., Ph.D.

The goals of the project are to determine the individual-as-unit PTEN genotype-organ-specific phenotype risk of cancer in individuals with PTEN mutations, as to determine the risk and age of onset of each type of cancer.

09/01/02-08/31/04

3) NIH/NCI 1R21CA030722-01

Title: Genetic etiologies of esophageal Barrett's and cancer

PI: Charis Eng, M.D., Ph.D.

This is a proposal to accrue families with Barrett esophagus and adenocarcinoma of the esophagus to begin whole genome scans to search for the predisposing gene(s).

08/01/00-07/31/03

4) Army Med R&D Command DAMD17-00-1-0390

Title: A Novel Phosphatase Gene on 10q23, MINPP, in Hereditary and Sporadic Breast Cancer

PI: Charis Eng, M.D., Ph.D.

The goals of the study are to explore whether another phosphatase which genetically localizes in proximity to PTEN and which has overlapping activity with PTEN could play a role in inherited and sporadic breast tumorigenesis as well.

03/25/02-04/24/05

5) Army Med R&D Command DAMD17-02-1-0528

Title: Genetics of Epithelial-Stromal Interactions in Hereditary Breast Cancer

PI: Charis Eng, M.D., Ph.D.

To determine the frequency of genetic alterations at various chromosomal loci across the genome in the epithelial and stromal compartments of BRCA1 invasive adenocarcinomas of the breast, to determine the clinical consequences of genetic alterations at various chromosomal loci across the genome in the epithelial and stromal compartments of BRCA1 invasive adenocarcinomas of the breast; and to determine the dependency of genetic alterations to one another in the epithelial and stromal compartments of BRCA1-related breast adenocarcinomas.

08/01/00-07/31/03

6) Army Med R&D Command DAMD17-02-1-0118

Title: Genetic Alterations in the Epithelial and Stromal Compartment of Prostate Adenocarcinomas

PI: Charis Eng, M.D., Ph.D.

The goal of this project is to examine, from a genetic point of view, the contribution of the epithelial and stromal compartments to human prostate carcinogenesis

03/01/01-02/28/04

7) V Foundation, Jimmy V Golf Classic Research Award

Title: Genetic Analysis of the Role of the Microenvironment in Epithelial Tumor Progression

PI's: Charis Eng, M.D., Ph.D., Gustavo Leone, Ph.D. and Michael C. Ostrowski, Ph.D.

The goal of this award is to provide seed moneys to gather preliminary data and make reagents related to tumor-microenvironmental interactions so that a group grant, e.g. PPG, may result from such work, as well as novel targets for therapy and prevention.

09/15/01-10/14/04

8) Army Med. R&D Command DAMD17-01-1-0357

Title: Rosiglitazone Therapy in Breast Cancer

PI: Lisa Yee, M.D.

Co-I: Charis Eng, M.D., Ph.D.

The goal of this study is to examine the anti-cancer effects of rosiglitazone, a synthetic ligand for PPARgamma, in early stage breast cancer as it relates to several genetic and molecular markers.

12/15/02-12/14/07

9) Doris Duke Distinguished Clinical Scientist Award

Title: Genetics of *PTEN* and molecular-based patient care

PI: Charis Eng, MD, PhD

This is an award for translational research and mentorship activities on the platform of the comprehensive analysis of PTEN in cancer as a paradigm for clinical cancer genetics translational research.